Surface Oncology Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.07
- Today's High:
- $1.07
- Open Price:
- $1.07
- 52W Low:
- $0.555
- 52W High:
- $1.43
- Prev. Close:
- $1.07
- Volume:
- 0
Company Statistics
- Market Cap.:
- $65.69 million
- Book Value:
- 0.81
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-37003000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -41.42%
- Return on Equity TTM:
- -105.78%
Company Profile
Surface Oncology Inc had its IPO on 2018-04-19 under the ticker symbol SURF.
The company operates in the Healthcare sector and Biotechnology industry. Surface Oncology Inc has a staff strength of 35 employees.
Stock update
Shares of Surface Oncology Inc opened at $1.07 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.07 - $1.07, and closed at $1.07.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Surface Oncology Inc have increased by 0%.
Surface Oncology Inc's Key Ratios
Surface Oncology Inc has a market cap of $65.69 million, indicating a price to book ratio of 0.4724 and a price to sales ratio of 1.6001.
In the last 12-months Surface Oncology Inc’s revenue was $0 with a gross profit of $-37003000 and an EBITDA of $-83164000. The EBITDA ratio measures Surface Oncology Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Surface Oncology Inc’s operating margin was 0% while its return on assets stood at -41.42% with a return of equity of -105.78%.
In Q2, Surface Oncology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Surface Oncology Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.66 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Surface Oncology Inc’s profitability.
Surface Oncology Inc stock is trading at a EV to sales ratio of 0.3304 and a EV to EBITDA ratio of 0.5889. Its price to sales ratio in the trailing 12-months stood at 1.6001.
Surface Oncology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $66.01 million
- Total Liabilities
- $16.83 million
- Operating Cash Flow
- $32.07 million
- Capital Expenditure
- $17000
- Dividend Payout Ratio
- 0%
Surface Oncology Inc ended 2024 with $66.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $66.01 million while shareholder equity stood at $49.18 million.
Surface Oncology Inc ended 2024 with $0 in deferred long-term liabilities, $16.83 million in other current liabilities, 6000.00 in common stock, $-252262000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.84 million and cash and short-term investments were $56.26 million. The company’s total short-term debt was $9,488,000 while long-term debt stood at $0.
Surface Oncology Inc’s total current assets stands at $60.59 million while long-term investments were $0 and short-term investments were $41.42 million. Its net receivables were $0 compared to accounts payable of $609000.00 and inventory worth $0.
In 2024, Surface Oncology Inc's operating cash flow was $32.07 million while its capital expenditure stood at $17000.
Comparatively, Surface Oncology Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.07
- 52-Week High
- $1.43
- 52-Week Low
- $0.555
- Analyst Target Price
- $2.38
Surface Oncology Inc stock is currently trading at $1.07 per share. It touched a 52-week high of $1.43 and a 52-week low of $1.43. Analysts tracking the stock have a 12-month average target price of $2.38.
Its 50-day moving average was $0.97 and 200-day moving average was $0.82 The short ratio stood at 0.45 indicating a short percent outstanding of 0%.
Around 727.7% of the company’s stock are held by insiders while 4603.3% are held by institutions.
Frequently Asked Questions About Surface Oncology Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.